A Study of CS1001 in Subjects With Stage IV Non-Small Cell Lung Cancer
A Multi-Center, Randomized, Double-Blind, Phase III Study of Platinum-Containing Chemotherapy With or Without CS1001 in Stage IV Non-Small Cell Lung Cancer Subjects
Sponsor: CStone Pharmaceuticals
A PHASE3 clinical study on Non Small Cell Lung Cancer, this trial is ongoing. The trial is conducted by CStone Pharmaceuticals and has accumulated 12 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Aug 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Aug 2025 [monthly]
Active Not Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 7 earlier versions
-
Dec 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
-
Nov 2021 — Dec 2022 [monthly]
Active Not Recruiting PHASE3
-
Mar 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2019 — Mar 2020 [monthly]
Recruiting PHASE3
-
Jan 2019 — Nov 2019 [monthly]
Recruiting PHASE3
First recorded
Dec 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CStone Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .